Journal of Genetic Syndromes & Gene Therapy

Journal of Genetic Syndromes & Gene Therapy
Open Access

ISSN: ISSN: 2157-7412

+32 28087017

Nancy Smyth Templeton

Nancy Smyth Templeton

Nancy Smyth Templeton
Director of Delivery Systems, Department of Molecular and Cellular Biology, Gradalis Inc?.
USA

Biography

Nancy Smyth Templeton is the Director of Delivery Systems at Gradalis Inc., Carrollton, TX. She received postdoctoral training at the National Institutes of Health in the National Cancer Institute and in the National Heart, Lung and Blood Institute, Bethesda, MD (1988-1994). She received a PhD in Molecular Biology and Biochemistry from Wesleyan University, Middletown, CT with her thesis research conducted at the Childrens Hospital Research Foundation, Cincinnati, Ohio upon her mentors move there (1983-1988). She received an MS in Genetics and Cell Biology from the University of Connecticut, Storrs, CT (1978-1982). She received a BS in Education and Sciences from CCNY, NYC, NY graduating magna cum laude (1974). She has received a Fulbright & Jaworski L.L.P. Faculty Excellence Award (for Enduring Educational Materials), Baylor College of Medicine, Houston, TX, a Fulbright & Jaworski L.L.P. Faculty Excellence Award (for Teaching and Evaluation), Baylor College of Medicine, Houston, TX and was awarded membership in the Academy of Distinguished Educators, Baylor College of Medicine, Houston, TX, the National Cancer Institute Officers Recognition EEO Award, NCI, NIH and other awards. She has served on 42 Grant Review Panels and Study Sections, 10 Professional Committees; reviewer for 20 peer-reviewed journals; editor of three editions of a Gene Therapy textbook; member of 8 Professional Societies, three clinical trials; has 54 publications; presented over 170 seminars as an invited speaker and/or moderator including national and international meetings; consultant for 5 Biotech and Pharmaceutical companies; and has 2 issued patents and 8 patent applications.

Research Interest

Liposomal delivery systems, Non-viral delivery systems, Targeted systemic delivery, Human clinical trials, Histone modifications, High-level gene expression, Homologous recombination, Plasmid DNA manufacture, Long-term gene expression.

Top